Breast cancer, Secondary cancers
Open
Phase 2/3
This trial is looking at a drug called izalontamab brengitecan for . It is comparing this to .
It is for people who:
have or
have breast cancer that has low levels of receptors for the hormones and and no receptors for . Your doctor will know this.
You pronounce izalontamab brengitecan as iz-uh-lon-too-mab braan-jit-eh-can.
Recruitment start: 1 October 2025
Recruitment end: 30 June 2028
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Peter Schmid
Bristol-Myers Squibb
Last reviewed: 21 May 2026
CRUK internal database number: 20115
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
